Soluble EpCAM levels in ascites correlate with positive cytology and neutralize catumaxomab activity in vitro

BMC Cancer

Volumn 15, Issue 1, 2015, Pages

  Seeber, Andreas ^a,b,c   Martowicz, Agnieszka ^a,d   Spizzo, Gilbert ^a,b,e   Buratti, Thomas ^e   Obrist, Peter ^f   Fong, Dominic ^a,e   Gastl, Guenther ^c   Untergasser, Gerold ^a,b,c  

^a TYROLEAN CANCER RESEARCH INSTITUTE   (Austria)

^b Center for Personalized Cancer Medicine GmbH   (Austria)

^c INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^d KAROLINSKA INSTITUTE   (Sweden)

^e Hospital of Merano   (Italy)

^f Hospital Zams   (Austria)

Author keywords

Ascites; Catumaxomab; Cytology; Elisa; Liver cirrhosis; Peritoneal carcinomatosis; Soluble EpCAM

Indexed keywords

CATUMAXOMAB; EPITHELIAL CELL ADHESION MOLECULE; YELLOW FLUORESCENT PROTEIN; BISPECIFIC ANTIBODY; CELL ADHESION MOLECULE; EPCAM PROTEIN, HUMAN; TUMOR ANTIGEN;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY SPECIFICITY; ARTICLE; ASCITES; CANCER PATIENT; CELL PROTECTION; CONTROLLED STUDY; CYTOLOGY; CYTOTOXICITY ASSAY; DRUG ACTIVITY; DRUG INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR SPACE; HUMAN; HUMAN CELL; IN VITRO STUDY; INTRACELLULAR SPACE; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; RETROSPECTIVE STUDY; TUMOR CELL; CELL PROLIFERATION; CYTOTOXICITY; DRUG EFFECTS; HEK293 CELL LINE; METABOLISM; NEOPLASM; PATHOLOGY; TUMOR CELL LINE;

ANTIBODIES, BISPECIFIC; ANTIGENS, NEOPLASM; ASCITES; CELL ADHESION MOLECULES; CELL LINE, TUMOR; CELL PROLIFERATION; CYTOTOXICITY, IMMUNOLOGIC; EPITHELIAL CELL ADHESION MOLECULE; HEK293 CELLS; HUMANS; LIVER CIRRHOSIS; NEOPLASMS; RETROSPECTIVE STUDIES;

EID: 84929150395     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/s12885-015-1371-1     Document Type: Article

References (31)

1. Runyon BA. Care of patients with ascites. N Engl J Med. 1994;330:337-42.
2. Feldman GB, Knapp RC. Lymphatic drainage of the peritoneal cavity and its significance in ovarian cancer. Am J Obstet Gynecol. 1974;119:991-4.
3. Runyon BA, Hoefs JC, Morgan TR. Ascitic fluid analysis in malignancy-related ascites. Hepatology. 1988;8:1104-9.
4. Seidman JD, Kurman RJ. Pathology of ovarian carcinoma. Hematol Oncol Clin North Am. 2003;17:909-25.
5. Singh MM, Pockros PJ. Hematologic and oncologic diseases and the liver. Clin Liver Dis. 2011;15:69-87.
6. Berman RS, Portera Jr CA, Ellis LM. Biology of liver metastases. Cancer Treat Res. 2001;109:183-206.
7. Motherby H, Nadjari B, Friegel P, Kohaus J, Ramp U, Bocking A. Diagnostic accuracy of effusion cytology. Diagn Cytopathol. 1999;20:350-7.
8. Mackey JR, Venner PM. Malignant ascites: demographics, therapeutic efficacy and predictors of survival. Can J Oncol. 1996;6:474-80.
9. Sadeghi B, Arvieux C, Glehen O, Beaujard AC, Rivoire M, Baulieux J, et al. Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer. 2000;88:358-63.
10. Kaleta EJ, Tolan NV, Ness KA, O'Kane D, Algeciras-Schimnich A. CEA, AFP and CA 19-9 analysis in peritoneal fluid to differentiate causes of ascites formation. Clin Biochem. 2013;46:814-8.
11. Nascimento I, Schaer R, Lemaire D, Freire S, Paule B, Carvalho S, et al. Vascular endothelial growth factor (VEGF) levels as a tool to discriminate between malignant and nonmalignant ascites. APMIS. 2004;112:585-7.
12. Kraft A, Weindel K, Ochs A, Marth C, Zmija J, Schumacher P, et al. Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease. Cancer. 1999;85:178-87.
13. Decker D, Stratmann H, Springer W, Schwering H, Varnai N, Bollmann R. Benign and malignant cells in effusions: diagnostic value of image DNA cytometry in comparison to cytological analysis. Pathol Res Pract. 1998;194:791-5.
14. Kielhorn E, Schofield K, Rimm DL. Use of magnetic enrichment for detection of carcinoma cells in fluid specimens. Cancer. 2002;94:205-11.
15. Spizzo G, Fong D, Wurm M, Ensinger C, Obrist P, Hofer C, et al. EpCAM expression in primary tumour tissues and metastases: an immunohistochemical analysis. J Clin Pathol. 2011;64:415-20.
16. Balzar M, Winter MJ, de Boer CJ, Litvinov SV. The biology of the 17-1A antigen (Ep-CAM). J Mol Med (Berl). 1999;77:699-712.
17. Maetzel D, Denzel S, Mack B, Canis M, Went P, Benk M, et al. Nuclear signalling by tumour-associated antigen EpCAM. Nat Cell Biol. 2009;11:162-71.
18. Chaves-Perez A, Mack B, Maetzel D, Kremling H, Eggert C, Harreus U, et al. EpCAM regulates cell cycle progression via control of cyclin D1 expression. Oncogene. 2013;32:641-50.
19. Petsch S, Gires O, Ruttinger D, Denzel S, Lippold S, Baeuerle PA, et al. Concentrations of EpCAM ectodomain as found in sera of cancer patients do not significantly impact redirected lysis and T-cell activation by EpCAM/CD3-bispecific BiTE antibody MT110. MAbs. 2011;3:31-7.
20. Sankpal NV, Mayfield JD, Willman MW, Fleming TP, Gillanders WE. Activator protein 1 (AP-1) contributes to EpCAM-dependent breast cancer invasion. Breast Cancer Res. 2011;13:R124.
21. Kimura H, Kato H, Faried A, Sohda M, Nakajima M, Fukai Y, et al. Prognostic significance of EpCAM expression in human esophageal cancer. Int J Oncol. 2007;30:171-9.
22. Tas F, Karabulut S, Serilmez M, Ciftci R, Duranyildiz D. Clinical significance of serum epithelial cell adhesion molecule (EPCAM) and vascular cell adhesion molecule-1 (VCAM-1) levels in patients with epithelial ovarian cancer. Tumour Biol. 2014;35:3095-102.
23. Punt CJ, Nagy A, Douillard JY, Figer A, Skovsgaard T, Monson J, et al. Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomised study. Lancet. 2002;360:671-7.
24. Spizzo G, Obrist P, Went P, Dirnhofer S, Gastl G. Edrecolomab in the adjuvant treatment of colorectal carcinoma. Lancet. 2003;361:83.
25. Zhang KH, Cao F, Fu QB, Zhu JQ, Chen J, Lv NH. Detection of mRNAs of GA733 genes by RT-PCR in exfoliated cells of pleural and peritoneal effusions and its clinical values. Intern Med. 2007;46:1489-94.
26. Heiss MM, Murawa P, Koralewski P, Kutarska E, Kolesnik OO, Ivanchenko VV, et al. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial. Int J Cancer. 2010;127:2209-21.
27. Runyon BA, Montano AA, Akriviadis EA, Antillon MR, Irving MA, McHutchison JG. The serum-ascites albumin gradient is superior to the exudate-transudate concept in the differential diagnosis of ascites. Ann Intern Med. 1992;117:215-20.
28. Peterson VM, Castro CM, Chung J, Miller NC, Ullal AV, Castano MD, et al. Ascites analysis by a microfluidic chip allows tumor-cell profiling. Proc Natl Acad Sci U S A. 2013;110:E4978-86.
29. de Boer CJ, van Krieken JH, Janssen-van Rhijn CM, Litvinov SV. Expression of Ep-CAM in normal, regenerating, metaplastic, and neoplastic liver. J Pathol. 1999;188:201-6.
30. Zhang L, Theise N, Chua M, Reid LM. The stem cell niche of human livers: symmetry between development and regeneration. Hepatology. 2008;48:1598-607.
31. Rupp AK, Rupp C, Keller S, Brase JC, Ehehalt R, Fogel M, et al. Loss of EpCAM expression in breast cancer derived serum exosomes: role of proteolytic cleavage. Gynecol Oncol. 2011;122:437-46.